BAX Baxter International Inc.

XNYS 24.92 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

BAX $24.92 —
Key stats
$24.92
52-Week Range
$15.73 – $30.00
YTD
+27.79%
IV Rank (30D)
61.79
Straddle Price
$2.75
P/C Vol Ratio
0.61
Market Cap
$13.1B
Open
$25.20
Day Range
$24.81 – $25.25
Volume
5,490,015
Prev Close
$25.29
Fair Value
MODEL: NEUTRAL

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY0.88
Cost of Equity (CAPM)9.34% (VRP-adj)
WACC7.79%
Volatility Risk Premium+32.5pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+4.4%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.04 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$0.8B
Return on Equity (TTM)-16.2%
Book / Price47.4% — banking bias active (P/B is primary)
Gross Margin (TTM)30.1%
FCF Margin (TTM)7.1%
Debt / Equity1.39
Quality Score1/6 — cyclical/struggling (5y DCF)
Market-Implied Growth+7.3% (reverse-DCF on current price)
SMA 50$24.74 (Market Anchor value)
SMA 20 / Bollinger Mid$24.57
Bollinger Width / SMA2044.7% (drives anchor stability)
Net Debt$6.5B
Market Cap$13B
Peers used for multiples: ABT, BDX, HUM, MDT, SYK (filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
9%
20-Day Fair Value
≈ by Nov 25, 2026
$25.18
α +1.1% rank 69%
conviction
61%
40-Day Fair Value
≈ by Dec 24, 2026
$25.63
α +2.9% rank 55%
conviction
83%
60-Day Fair Value
≈ by Jan 22, 2027
$24.98
α +0.2% rank 53%
conviction
9%
MethodImplied PriceWeightDetail
DCF $20.80 24%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 33.1× · 5 peers
Peer EV/EBITDA $27.72 7% median 18.9× · 5 peers
Peer P/B $31.67 9% median 2.6× · 5 peers
Peer P/S $75.58 9% median 3.2× · 5 peers
Market Anchor (SMA50) $24.74 30% stability 62% (BB-width)
Options Expected (B-L 30d) $24.42 20% 17 strikes · skew -0.23
As of 2026-10-27 · updated
About
Industry (SIC)
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
Exchange
XNYS
Market Cap
$13.1B
Employees
37,500
List Date
1961-05-15
CIK
0000010456
Next Earnings
2026-10-29 (Pre-Market)
EPS Forecast
$0.51 (8 est.)
Headquarters
Deerfield, IL
Homepage
https://www.baxter.com

Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan-4.11%-1.65%-10.48%-0.41%11.28%2.92%-0.41%
Feb1.72%0.05%-13.68%4.41%9.07%2.52%0.68%
Mar8.21%-7.84%3.84%4.22%-1.81%-14.68%-1.34%
Apr1.62%-9.57%19.26%-7.30%-8.38%4.77%0.07%
May-5.11%7.70%-14.06%-15.49%-0.55%9.12%-3.06%
Jun-2.00%-13.75%10.50%-1.85%2.47%15.87%1.87%
Jul-5.06%-10.43%1.23%8.35%-30.32%20.30%-2.65%
Aug-1.28%-2.06%-9.78%5.36%12.43%-7.47%-0.47%
Sep3.65%-5.11%-7.04%0.32%-5.79%-5.81%-3.30%
Oct-2.87%-2.28%-13.17%-3.28%-20.93%5.41%*-6.19%
Nov-6.58%5.19%10.03%-6.02%2.91%--1.11%
Dec14.33%-2.69%5.77%-13.08%0.16%--0.90%
Total0.52%-36.57%-22.03%-24.60%-33.07%31.80%-13.99%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $24.64
SMA 50: $24.72
SMA 200: $21.28
Current: $24.92
EMA 12: $24.95
EMA 26: $24.70
MACD: 0.2484 | Signal: 0.0703
BULLISH
ADX (14): 20.85
WEAK TREND
+DI: 24.35
−DI: 19.73

Momentum Oscillators

RSI (14): 52.48
NEUTRAL
Stoch %K: 67.20
Stoch %D: 71.94
Williams %R: -42.86

Volume & Volatility

BB Upper: $25.90
BB Lower: $23.38
NEUTRAL
OBV: 13,848,133
Vol SMA 20: 5,916,077
Vol ROC: 68.94%
ATR: $0.72
True Range: $0.48
HV 20: 29.8%
HV 30: 27.3%
HV 60: 26.6%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-29T00:00:00 – 2026-10-27T00:00:00
AI Analysis

LLM Stock Analysis Report

SYMBOL: BAX

Executive Summary Overall assessment: NEUTRAL (confidence level 6/10) Key drivers: Strong technical signals, positive news sentiment Primary risks: High volatility, negative earnings surprises Investment thesis: BAX has a strong upward momentum, driven by positive news and technical indicators. However, the stock is not oversold and may have some room for further upside before facing resistance. Recent news sentiment impact: Positive news headlines have contributed to the recent price increase.

Technical Analysis Trend Direction:

  • Short-term (1-4 weeks): Bullish
  • Medium-term (1-3 months): Bullish
  • Long-term (3-12 months): Neutral

Support/Resistance Levels:

  • Upper: $29.78 (Bollinger Band resistance)
  • Middle: $26.12 (SMA 20 support)

Momentum Signals:

  • RSI interpretation: Neutral (58.91), indicating no clear buy or sell signal
  • MACD signal: Bullish, with a bullish crossover above the signal line
  • Bollinger Bands position: Neutral, showing no significant mean reversion or breakout

Volume Analysis:

  • Volume trends: No clear trend detected
  • Institutional interest signals: Medium-high institutional buying

News & Sentiment Analysis Recent Headlines Summary:

  1. Positive news on Baxter International's stock performance
  2. Global Human Fibrinogen Concentrate Market Size/Share analysis
  3. Negative news on Becton Dickinson's valuation
  4. Robotic Pharmacy Prescription Market research and forecast report
  5. Exclusive news on Iran war's impact on medical supplies
  6. Manufacturing disruption affecting Baxter Cancer Drug supply

Sentiment Assessment: Positive (60%), with 40% neutral or negative sentiment.

Catalyst Identification:

  1. Earnings release in Q3, potentially driving price action

Market Narrative: The technical analysis indicates a strong upward momentum, driven by positive news and indicators. However, the recent news headlines suggest that the market may be anticipating some volatility in the near term.

Risk & Volatility Assessment Beta Interpretation: High-risk stock (beta 1.18)

Volatility Regime: Above average volatility

Options Market Signals:

  • IV rank: Medium
  • Put/call ratios: Bullish, with a put/call volume ratio of 0.10 and open interest ratio of 0.60

Downside Protection: Support levels at $22.46 (Bollinger Band lower band) and $19.87 (SMA 200).

Market Context & Positioning Sector Performance:

  • Relative strength vs sector/market: Above average performance in the medical technology sector

Institutional Activity:

  • Volume patterns suggesting institutional interest: Medium-high buying pressure

Correlation Analysis:

  • Stock moves relative to market: Correlation coefficient of 0.35, indicating above-average amplification of market movements.

Relative Valuation:

  • Position within trading range: Near the top end of a trading range, with room for further upside before facing resistance.

Key Levels & Action Items Critical Price Levels:

  • Support at $22.46 (Bollinger Band lower band)
  • Resistance at $29.78 (Bollinger Band upper band)

Breakout/Breakdown Levels:

  • Breakout above the Bollinger Band upper band ($29.78) could trigger significant buying pressure
  • Breakdown below the SMA 200 support level ($19.87) could lead to further price decline

Time-Sensitive Catalysts:

  1. Earnings release in Q3, potentially driving price action

Risk Management: Stop-loss levels: $24.00 (below the recent low) Position sizing considerations: Reduce position size due to high volatility and potential market corrections.

Please note that this report is based on the data provided and should not be considered as personalized investment advice.

Generated
News
All BAX news →
Earnings History
14 of 23 under expected move
Avg Expected Move
5.08%
Avg Actual Move
5.81%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-01-11 Pre-Market 3.24% 0.94% 0.29x Within
2021-04-29 Pre-Market 4.14% 1.89% 0.46x Within
2021-07-29 Pre-Market 3.64% 5.53% 1.52x Exceeded
2021-10-28 Pre-Market 4.52% 4.06% 0.90x Within
2022-02-17 Pre-Market 3.47% 2.74% 0.79x Within
2022-04-28 Pre-Market 4.92% 0.38% 0.08x Within
2022-07-28 Pre-Market 4.34% 10.93% 2.52x Exceeded
2022-10-27 Pre-Market 4.95% 6.35% 1.28x Exceeded
2023-02-09 Pre-Market 4.82% 12.13% 2.52x Exceeded
2023-04-27 Pre-Market 6.12% 1.56% 0.25x Within
2023-07-27 Pre-Market 4.84% 7.09% 1.46x Exceeded
2023-11-02 Pre-Market 5.28% 4.45% 0.84x Within
2024-02-08 Pre-Market 6.73% 2.74% 0.41x Within
2024-05-02 Pre-Market 6.15% 8.50% 1.38x Exceeded
2024-08-06 After-Close 2.03% 0.89% 0.44x Within
2024-11-08 Pre-Market 6.38% 3.88% 0.61x Within
2025-02-03 After-Close 3.08% 0.70% 0.23x Within
2025-05-01 Pre-Market 5.77% 1.60% 0.28x Within
2025-07-31 Pre-Market 4.01% 22.42% 5.59x Exceeded
2025-10-30 Pre-Market 10.04% 14.54% 1.45x Exceeded
2026-02-12 Pre-Market 10.33% 15.99% 1.55x Exceeded
2026-04-30 After-Close 3.84% 2.10% 0.55x Within
2026-07-30 After-Close 4.21% 2.21% 0.52x Within

Earnings calendar: this week’s reports with expected vs actual moves →

BAX Options Activity & IV Rank

BAX IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 49.1%
7-DTE IV: 82.5%
Expected Move: $2.75
7-DTE Move: $2.45
Days to Exp: 31 (2026-11-27)

Options Flow

Call Volume: 33
Put Volume: 20
P/C Volume: 0.606
BULLISH
Call OI: 56
Put OI: 20
P/C OI: 0.357
Total OI: 76

ATM Options Pricing

ATM Call: $1.35
ATM Put: $1.40
Call %: 5.4%
Put %: 5.6%

Chain Summary

Chain Volume: 5,300
Chain OI: 83,951
Last Updated: 10/27/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 58th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
58%
vs own history
GEX tilt
+0.45
OI-weighted, today
Vanna tilt
+0.43
δ-sensitivity to IV
Charm tilt
-0.73
δ-decay vs time
Vanna tilt +0.43: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.73: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 57 ATM contracts, 24k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM 58.6% / Wing —
30 DTE / 10d —
— pts EXTREME
ATM 47.4% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)90.5HighOct 27
IV Rank (30 DTE)61.8MediumOct 27
Straddle Price (30 DTE)$2.75Oct 27
Beta Analysis

Risk Metrics

Beta: 1.1183
Alpha: 2.91%
Correlation: 0.3282
R-Squared: 10.8%
Stock Volatility: 43.3%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own BAX
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$4.7M
0.00%
#2135 of 6285-82.8%13F
Rockefeller Capital Management Family office
Rockefeller family
$416K
0.00%
#2182 of 4729-47.1%13F
Bridgewater Associates Hedge fund
Ray Dalio
$370K
0.00%
#954 of 997+8.0%13F
Millennium Management Hedge fund
Izzy Englander
$215K
0.00%
#3460 of 3716-99.4%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

BAX Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 515,000,000 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

733 filers621,657,625 shares$13.15B value120.71% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 81,842,105 $1.74B 13.27% 15.89% 2026-06-30
2 PZENA INVESTMENT MANAGEMENT LLC 65,295,393 $1.39B 10.59% 12.68% 2026-06-30
3 Dodge & Cox 58,386,345 $1.24B 9.47% 11.34% 2026-06-30
4 Vanguard Group Inc Custodian 62,635,136 $1.20B 9.10% 12.16% 2025-12-31
5 FMR LLC Custodian 53,913,831 $1.15B 8.74% 10.47% 2026-06-30
6 Vanguard Capital Management LLC 33,754,280 $719.64M 5.47% 6.55% 2026-06-30
7 Vanguard Portfolio Management LLC 24,057,190 $512.90M 3.90% 4.67% 2026-06-30
8 State Street Corp 20,600,468 $439.40M 3.34% 4.00% 2026-06-30
9 GREENHAVEN ASSOCIATES INC 14,285,228 $304.56M 2.32% 2.77% 2026-06-30
10 Geode Capital Management, LLC Custodian 14,123,689 $300.59M 2.29% 2.74% 2026-06-30
11 Invesco Ltd. Custodian 12,361,881 $263.56M 2.00% 2.40% 2026-06-30
12 UBS Group AG Custodian 9,529,309 $203.16M 1.55% 1.85% 2026-06-30
13 First Pacific Advisors, LP 7,618,145 $162.42M 1.24% 1.48% 2026-06-30
14 Goldman Sachs Group Inc Custodian 7,150,462 $152.45M 1.16% 1.39% 2026-06-30
15 EQUITY INVESTMENT CORP 6,886,265 $146.82M 1.12% 1.34% 2026-06-30
16 Morgan Stanley Custodian 6,359,790 $135.59M 1.03% 1.23% 2026-06-30
17 Bank of America Corp Custodian 6,237,950 $132.99M 1.01% 1.21% 2026-06-30
18 State Farm Mutual Automobile Insurance Co 6,225,060 $132.72M 1.01% 1.21% 2026-06-30
19 Charles Schwab Investment Management, Inc. 5,996,711 $127.85M 0.97% 1.16% 2026-06-30
20 Dimensional Fund Advisors LP Custodian 5,612,144 $119.68M 0.91% 1.09% 2026-06-30
21 Northern Trust Corp Custodian 4,864,004 $103.70M 0.79% 0.94% 2026-06-30
22 Marshall Wace, LLP Custodian 4,857,267 $103.56M 0.79% 0.94% 2026-06-30
23 Norges Bank 4,144,905 $88.37M 0.67% 0.80% 2026-06-30
24 LSV ASSET MANAGEMENT 3,914,800 $83.46M 0.63% 0.76% 2026-06-30
25 RWC Asset Management LLP 3,122,618 $74.94M 0.57% 0.61% 2026-09-30
19 filers$91.03M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $28.00M 30.76% 2026-06-30
2 Great Hill Capital LLC $19.70M 21.64% 2026-09-30
3 Citadel Advisors LLC Custodian $13.00M 14.28% 2026-06-30
4 Point72 Asset Management, L.P. $6.74M 7.41% 2026-06-30
5 Jane Street Group, LLC Custodian $5.86M 6.44% 2026-06-30
6 NOMURA HOLDINGS INC $5.09M 5.60% 2026-06-30
7 Walleye Trading LLC $3.59M 3.94% 2026-06-30
8 Wolverine Trading, LLC Custodian $2.49M 2.74% 2025-09-30
9 D. E. Shaw & Co., Inc. Custodian $1.20M 1.32% 2026-06-30
10 CAPITAL FUND MANAGEMENT S.A. $933.82K 1.03% 2026-06-30
11 Cubist Systematic Strategies, LLC $812.89K 0.89% 2025-09-30
12 Two Sigma Investments, LP Custodian $754.73K 0.83% 2026-06-30
13 CAPSTONE INVESTMENT ADVISORS, LLC $750.46K 0.82% 2026-06-30
14 Walleye Capital LLC $601.22K 0.66% 2026-06-30
15 Millennium Management LLC Custodian $449.85K 0.49% 2026-06-30
16 TUDOR INVESTMENT CORP ET AL $381.63K 0.42% 2026-06-30
17 Alphadyne Asset Management LP $353.91K 0.39% 2026-06-30
18 J. Goldman & Co LP $238.78K 0.26% 2026-06-30
19 Arkadios Wealth Advisors $78.88K 0.09% 2026-06-30
16 filers$57.79M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $25.26M 43.71% 2026-06-30
2 Citadel Advisors LLC Custodian $9.47M 16.39% 2026-06-30
3 Point72 Asset Management, L.P. $5.89M 10.20% 2026-06-30
4 CAPITAL FUND MANAGEMENT S.A. $2.68M 4.64% 2026-06-30
5 Walleye Capital LLC $2.58M 4.46% 2026-06-30
6 Jane Street Group, LLC Custodian $2.32M 4.01% 2026-06-30
7 Millennium Management LLC Custodian $2.01M 3.48% 2026-06-30
8 Wolverine Trading, LLC Custodian $1.83M 3.17% 2025-09-30
9 CAPSTONE INVESTMENT ADVISORS, LLC $1.52M 2.63% 2026-06-30
10 D. E. Shaw & Co., Inc. Custodian $1.45M 2.51% 2026-06-30
11 Two Sigma Investments, LP Custodian $782.44K 1.35% 2026-06-30
12 Walleye Trading LLC $631.07K 1.09% 2026-06-30
13 Alphadyne Asset Management LP $398.68K 0.69% 2026-06-30
14 Squarepoint Ops LLC $396.55K 0.69% 2026-06-30
15 TUDOR INVESTMENT CORP ET AL $296.35K 0.51% 2026-06-30
16 Cubist Systematic Strategies, LLC $266.41K 0.46% 2025-09-30

BAX Insider Trading (Form 4)

Latest: 2026-09-03
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-03 Andrew P. Hider President and CEO Tax (F) −54,276 $25.70 -$1.39M EDGAR
2026-09-03 James Teaff President, CCS Tax (F) −750 $25.48 -$19.1K EDGAR
2026-09-03 Julie Foster President, Front Line Care Tax (F) −2,098 $25.70 -$53.9K EDGAR
2026-06-03 James Teaff President, CCS Tax (F) −321 $18.68 -$6.0K EDGAR
2026-06-03 Steven P. Wallace President, Adv. Surgery Tax (F) −153 $18.68 -$2.9K EDGAR
2026-06-03 Anita A Zielinski SVP, Interim CFO, CAO & Cntrlr Award (A) +13,426 — EDGAR
2026-05-07 William A. Ampofo II Director Award (A) +12,836 — EDGAR
2026-05-07 Jeffrey A Craig Director Award (A) +12,836 — EDGAR
2026-05-07 Michael R. McDonnell Director Award (A) +12,836 — EDGAR
2026-05-07 David Brent Shafer Director Award (A) +12,836 — EDGAR
2026-05-07 Patricia Morrison Director Award (A) +12,836 — EDGAR
2026-05-07 Nancy M Schlichting Director Award (A) +12,836 — EDGAR
2026-05-07 Amy McBride Wendell Director Award (A) +12,836 — EDGAR
2026-05-07 David S. Wilkes Director Award (A) +12,836 — EDGAR
2026-03-10 Joel T. Grade EVP and CFO Tax (F) −8,153 $17.69 -$144.2K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

BAX Insider Holdings

27 insiders · @ $24.92
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Jose E Almeida Chairman, CEO, President 568,565 $14.17M $499.8K 23 2024-12-17
2 Andrew P. Hider President and CEO 518,447 $12.92M $0 3 2026-09-03
3 Joel T. Grade EVP and CFO 271,674 $6.77M $0 9 2026-03-10
4 Jeanne K Mason EVP, Chief HR Officer 199,853 $4.98M -$26.00M 57 2025-12-16
5 Heather Knight EVP, Chief Operating Officer 177,362 $4.42M $0 11 2025-03-10
6 David S. Rosenbloom EVP and General Counsel 138,216 $3.44M $0 12 2026-03-10
7 Alok Sonig EVP,Group President,Pharma 128,219 $3.20M $0 8 2025-09-04
8 Reazur Rasul EVP,Group Pres,Healthcare 125,557 $3.13M $0 14 2026-03-10
9 Christopher A. Toth EVP, Group Pres, Kidney Care 105,186 $2.62M $0 5 2025-02-04
10 Maria Cecilia Soriano Group Pres., ITT & Pharma. 75,045 $1.87M $0 3 2026-03-10
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

BAX Board & Officers

As of SEC filings through Oct 2, 2026

Directors 10

Officers 13

  • Andrew P. Hider · President and CEO · since Aug 19, 2025
  • Cynthia Carlisle · Executive Vice President, CHRO · since Feb 23, 2026
  • James Teaff · President, CCS · since Apr 1, 2026
  • Julie Foster · President, Front Line Care · since Apr 1, 2026
  • Steven P. Wallace · President, Adv. Surgery · since Apr 1, 2026
  • Terence John Rogers · EVP and CFO · since Oct 1, 2026
  • Jeanne K Mason · EVP, Chief HR Officer · listed since Feb 2024
  • James W Borzi · EVP,Chief Supply Chain Officer · listed since Mar 2024
  • David S. Rosenbloom · EVP and General Counsel · listed since Mar 2024
  • Reazur Rasul · EVP, Group Pres, Healthcare · since Mar 1, 2023
  • Anita A Zielinski · SVP, CAO and Controller · since Feb 21, 2025
  • Maria Cecilia Soriano · Group Pres., ITT & Pharma. · since Dec 1, 2025
  • Bernard Heine · AVP, Finance InterimCAO&Cntrlr · since Sep 15, 2026
Changes in the last 10 years (71)
Oct 1, 2026Terence John Rogers became EVP and CFO
Sep 15, 2026Bernard Heine became AVP, Finance InterimCAO&Cntrlr
Apr 1, 2026Steven P. Wallace became President, Adv. Surgery
Apr 1, 2026Julie Foster became President, Front Line Care
Apr 1, 2026James Teaff became President, CCS
Feb 23, 2026Cynthia Carlisle became Executive Vice President, CHRO
Feb 13, 2026Michael R. McDonnell became a director
Feb 10, 2026The company announced the departure of Stephen H Rusckowski from the board in an SEC filing
Feb 10, 2026The company announced the departure of Cathy R Smith from the board in an SEC filing
Dec 1, 2025Maria Cecilia Soriano became Group Pres., ITT & Pharma.
Nov 5, 2025The company announced the departure of Alok Sonig as EVP,Group President,Pharma in an SEC filing
Aug 21, 2025David Brent Shafer no longer listed as Interim CEO and Chair in SEC filings
Aug 19, 2025Andrew P. Hider became a director
Aug 19, 2025Andrew P. Hider became President and CEO
Mar 5, 2025Heather Knight listed as EVP, Chief Operating Officer (previously EVP, Group Pres, Med Products) in SEC filings
Feb 21, 2025Anita A Zielinski became SVP, CAO and Controller
Feb 6, 2025David Brent Shafer first listed as Interim CEO and Chair in an SEC filing
Feb 4, 2025Christopher A. Toth reported in an SEC filing no longer being EVP,Group Pres, Kidney Care
Nov 18, 2024The company announced the departure of Peter M Wilver from the board in an SEC filing
Sep 8, 2024Jeffrey A Craig became a director
Not reported recently (20)
  • Joel T. Grade · Last reported as EVP and CFO in an SEC filing dated Mar 10, 2026
  • Heather Knight · Last reported as EVP, Chief Operating Officer in an SEC filing dated Mar 10, 2025
  • Jose E Almeida · Last reported as Chairman, CEO and President in an SEC filing dated Dec 17, 2024
  • Cristiano Franzi · Last reported as SVP, President, EMEA in an SEC filing dated Mar 6, 2023
  • Jacqueline Kunzler · Last reported as SVP, Chief Quality Officer in an SEC filing dated Mar 6, 2023
  • Steven Flynn · Last reported as SVP, President, APAC in an SEC filing dated Mar 3, 2023
  • Sean Martin · Last reported as SVP and General Counsel in an SEC filing dated Mar 4, 2022
  • Andrew Frye · Last reported as SVP, President, APAC in an SEC filing dated Mar 4, 2022
  • Thomas T Stallkamp · Last reported as a director in an SEC filing dated May 6, 2021
  • James R Gavin III · Last reported as a director in an SEC filing dated Sep 15, 2020
  • Alex N Blanco · Last reported as SVP, Chief Supply Chain Offcr in an SEC filing dated Apr 1, 2020
  • Scott Pleau · Last reported as SVP, Operations in an SEC filing dated Apr 2, 2019
  • Brik V Eyre · Last reported as SVP, President, Americas in an SEC filing dated Mar 4, 2019
  • Carole J Shapazian · Last reported as a director in an SEC filing dated Dec 17, 2018
  • Kornelis J. Storm · Last reported as a director in an SEC filing dated Mar 30, 2018
  • Caroline Karp · Last reported as SVP, Controller in an SEC filing dated Mar 7, 2018
  • Paul Vibert · Last reported as CVP, International in an SEC filing dated Mar 8, 2017
  • Marcus Schabacker · Last reported as CVP, Chief Scientific Officer in an SEC filing dated Mar 8, 2017
  • David P. Scharf · Last reported as CVP and General Counsel in an SEC filing dated Feb 23, 2017
  • Robert Felicelli · Last reported as CVP, Business Transformation in an SEC filing dated Jan 3, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

BAX Proposed Insider Sales (Form 144)

Latest: 2026-05-18
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-05-18 STEPHEN N. OESTERLE REV TRUST Former Affiliate 36,347 $645.2K 2026-05-18 Morgan Stanley Smith Barney LLC … — EDGAR
2024-09-16 Stevens Brian Officer 976 $39.0K 2024-09-16 MORGAN STANLEY SMITH BARNEY LLC … — EDGAR
2024-09-13 Stevens Brian Officer 16,063 $639.5K 2024-09-13 MORGAN STANLEY SMITH BARNEY LLC … — EDGAR
2024-03-01 JEANNE MASON Officer 64,488 $2.62M 2024-03-01 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-05-08
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Accession Link
2026-05-08 0001193125-26-214680 EDGAR
2026-04-30 0001628280-26-028582 EDGAR
2026-03-19 0001193125-26-116114 EDGAR
2026-03-16 0001193125-26-107345 EDGAR
2026-02-12 0001628280-26-007474 EDGAR
2025-12-22 0000010456-25-000025 EDGAR
2025-12-04 0001628280-25-055359 EDGAR
2025-11-25 0001628280-25-054015 EDGAR
2025-11-19 0001628280-25-053056 EDGAR
2025-11-19 0001628280-25-053187 EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-12 0001628280-26-007733 EDGAR
2025-02-21 0001628280-25-007201 EDGAR
2024-02-08 0001628280-24-003932 EDGAR
2023-02-09 0001628280-23-002864 EDGAR
2022-02-23 0001628280-22-003432 EDGAR
2021-02-11 0001628280-21-001867 EDGAR
2020-03-17 0001628280-20-003693 EDGAR
2019-02-21 0001564590-19-003727 EDGAR
2018-02-23 0001564590-18-002954 EDGAR
2017-02-23 0001564590-17-002240 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-04-30 0001628280-26-028962 EDGAR
2025-11-04 0001628280-25-048897 EDGAR
2025-08-05 0001628280-25-037877 EDGAR
2025-05-06 0001628280-25-022727 EDGAR
2024-11-12 0001628280-24-047221 EDGAR
2024-08-06 0001628280-24-034965 EDGAR
2024-05-02 0001628280-24-019786 EDGAR
2023-11-02 0001628280-23-036195 EDGAR
2023-07-27 0001628280-23-025825 EDGAR
2023-04-27 0001628280-23-013357 EDGAR
ETF Holders
186 ETFs hold BAX
25 shown · $2.29B total exposure · 0.03% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.02% $394.8M — 2026-09-30
2 VOO Vanguard S&P 500 ETF Vanguard 0.02% $325.8M — 2026-09-30
3 VB Vanguard Morningstar Small-Cap ETF Vanguard 0.16% $279.3M — 2026-09-30
4 RSP Invesco S&P 500 Equal Weight ETF Invesco 0.20% $203.7M — 2026-10-24
5 IVV iShares Core S&P 500 ETF iShares (BlackRock) 0.02% $174.0M $880.6B 2026-10-23
6 VBR Vanguard Morningstar Small-Cap Value ETF Vanguard 0.26% $164.5M — 2026-09-30
7 SPY State Street® SPDR® S&P 500® ETF Trust SPDR (State Street) 0.02% $161.8M $807.9B 2026-10-23
8 XLV State Street® Health Care Select Sector SPDR® ETF SPDR (State Street) 0.20% $94.4M $47.0B 2026-10-23
9 IHI iShares U.S. Medical Devices ETF iShares (BlackRock) 1.71% $61.4M $3.6B 2026-10-23
10 IWR iShares Russell Mid-Cap ETF iShares (BlackRock) 0.10% $54.5M $57.3B 2026-10-23
11 DFAS Dimensional US Small Cap ETF Dimensional 0.15% $50.7M — 2026-10-23
12 VYM Vanguard High Dividend Yield ETF Vanguard 0.05% $50.1M — 2026-09-30
13 VHT Vanguard Health Care ETF Vanguard 0.17% $37.9M — 2026-09-30
14 SPYM State Street® SPDR® Portfolio S&P 500® ETF SPDR (State Street) 0.02% $36.2M $181.7B 2026-10-23
15 IWD iShares Russell 1000 Value ETF iShares (BlackRock) 0.03% $29.0M $84.8B 2026-10-23
16 SCHM Schwab U.S. Mid-Cap ETF Nport 0.18% $26.1M — 2026-05-31
17 IVE iShares S&P 500 Value ETF iShares (BlackRock) 0.04% $21.7M $50.6B 2026-10-23
18 IWS iShares Russell Mid-Cap Value ETF iShares (BlackRock) 0.13% $19.8M $15.7B 2026-10-23
19 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.02% $17.2M $96.5B 2026-10-23
20 RPV Invesco S&P 500 Pure Value ETF Invesco 0.95% $16.6M — 2026-10-24
21 SPYV State Street® SPDR® Portfolio S&P 500® Value ETF SPDR (State Street) 0.04% $16.6M $38.6B 2026-10-23
22 RSPH Invesco S&P 500 Equal Weight Health Care ETF Invesco 1.59% $15.3M — 2026-10-24
23 FNDX Schwab Fundamental U.S. Large Company ETF Nport 0.06% $14.6M — 2026-05-31
24 IUSV iShares Core S&P U.S. Value ETF iShares (BlackRock) 0.04% $11.6M $28.4B 2026-10-23
25 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.03% $11.4M — 2026-10-23
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-1.96
TTM Revenue
$11.47B
TTM Net Income
$-1.01B
TTM Op. Cash Flow
$1.32B
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$2.96B$126.00M$0.24$285.00M
Q1 '262026-03-31$2.70B$-15.00M$-0.03$213.00M
Q4 '252025-12-31$2.97B$-1.07B$-2.08$584.00M
Q3 '252025-09-30$2.83B$-46.00M$-0.09$237.00M
Q2 '252025-06-30$2.81B$91.00M$0.18$217.00M
Q1 '252025-03-31$2.62B$126.00M$0.25$-193.00M
Q4 '242024-12-31$2.75B$-189.00M$-0.37$449.00M
Q3 '242024-09-30$2.70B$140.00M$0.27$292.00M
Q2 '242024-06-30$2.69B$-314.00M$-0.61$115.00M
Q1 '242024-03-31$2.49B$37.00M$0.07$163.00M
Q4 '232023-12-31$2.73B$245.00M$0.47$531.00M
Q3 '232023-09-30$2.60B$2.51B$4.93$365.00M
Q2 2026 • period ending 2026-06-30 • filed 2026-07-30
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.08
P/S
1.12
EV/EBITDA
18.38
EV/Sales
1.68
ROE
-16.3%
ROA
-5.1%
Div Yield
1.41%
FCF Yield
10.28%
Debt/Equity
1.39
Current Ratio
—
Market Cap
$12.83B
as of 2026-10-27
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
24.37M
SI % of Float
4.75%
Days to Cover
2.98
Short Vol Ratio
41.6%
Free Float
512.86M
Float %
99.2%
Short interest 2026-09-30 • Short volume 2026-10-27 • Float 2026-08-24